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ABSTRACT The swine-origin H1N1 influenza A virus emerged in early 2009 and caused the first influenza pandemic in 41 years.
The virus has spread efficiently to both the Northern and the Southern Hemispheres and has been associated with over 16,000
deaths. Given the virus’s recent zoonotic origin, there is concern that the virus could acquire signature mutations associated
with the enhanced pathogenicity of previous pandemic viruses or H5N1 viruses with pandemic potential. We tested the hypothe-
sis that mutations in the polymerase PB2 gene at residues 627 and 701 would enhance virulence but found that influenza viruses
containing these mutations in the context of the pandemic virus polymerase complex are attenuated in cell culture andmice.
IMPORTANCE Influenza A virus (IAV) evolution is characterized by host-specific lineages, and IAVs derived in whole or in part
from animal reservoirs have caused pandemics in humans. Because IAVs are known to acquire host-adaptive genomemutations,
and since the PB2 gene of the 2009 H1N1 virus is of recent avian derivation, there exists concern that the pathogenicity of the
2009 H1N1 influenza A pandemic virus could be potentiated by acquisition of the host-adaptive PB2-E627K or -D701Nmuta-
tions, which have been shown to enhance the virulence of other influenza viruses. We present data from amouse model of influ-
enza infection showing that suchmutations do not increase the virulence of viruses containing the 2009 H1N1 viral polymerase.
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Influenza A viruses (IAVs) cause significant human respiratorydisease in the form of annual, epidemic recurrences and the
sporadic emergence of novel viruses thatmay give rise to pandem-
ics (1). In April 2009, a novel swine-originH1N1 influenza A virus
was identified from patients in Mexico and the United States (2),
spread globally (3), and caused the first influenza pandemic since
1968 (4). Influenza pandemics vary greatly in their severity, as
measured by the numbers of pneumonia and influenza deaths
they cause (5). While the pandemic’s full impact cannot yet be
assessed, as of 21 February 2010 there have been at least 16,226
deaths and millions of cases worldwide (6). The worst influenza
pandemic on record was the 1918-1919 “Spanish” influenza,
which killed approximately 50 million people globally (7). It has
been hypothesized that the 1918 pandemic circulated in a less
virulent form in an initial spring-summer wave and a more viru-
lent form in a second major wave (8). There has been speculation
that the 2009 pandemic could also develop enhanced virulence
following further adaptation to the human host, but data in sup-
port of these hypotheses are limiting (9).
The basis for enhanced pathogenicity of pandemic influenza
viruses relates in part to antigenic novelty and the lack of protec-
tive immunity in all or parts of the population but also likely
relates to inherent viral virulence factors that differ between virus
strains. Pandemic viruses, derived at least in part from zoonotic
infections,must also be sufficiently host adapted to efficiently rep-
licate and transmit in humans (10). Themolecular basis as to why
the 1918 pandemic virus, especially in the fall and winter of 1918-
1919 (11), had enhanced pathogenicity is polygenic and still not
fully elucidated. Experimental animalmodels have shown that the
genes encoding the surface proteins hemagglutinin (HA) and
neuraminidase (NA) and the genes encoding the viral ribonucle-
oprotein polymerase (RNP) complex (consisting of the viral poly-
merase subunits PB2, PB1, PA, and nucleoprotein [NP]) contain
still-undefined virulence factors (12–16). Similarly, the Asian lin-
eage of highly pathogenic avian influenza (HPAI) virus H5N1 has
caused very high mortality rates among those humans with clini-
cally apparent infections (286 deaths out of 478 confirmed cases
since 2003 [17]), but sustained human-to-human transmission
has not been observed.
Mutations in the genes encoding the influenza A viral RNP
have been implicated in the adaptation of avian influenza viruses
to humans (18, 19). The PB2 subunit (20), in particular, PB2 res-
idue 627 (PB2-627), has been identified as an important determi-
nant of host range restriction (21) and virulence in animalmodels
(22, 23). Avian influenza viruses generally encode a glutamic acid
at this site, while human isolates typically encode a lysine. Residue
701, residing in a region of PB2 implicated in nuclear localization
(24, 25), has similarly been identified as a host-adaptive locus (26),
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with the D701Nmutation increasing both replication inmice (27,
28) and transmission in guinea pigs (29). Independent examples
of selection of the PB2-D701Nmutation have also been observed,
for example, in the nonpandemic avian origin European swine
H1N1 viruses (30) as well as in some HPAI H5N1 viruses.
Alongwith its established role in host adaptation, the influenza
A RNP has also been noted as a key determinant of virulence. A
virus containing the 1918 RNP on the background of a seasonal
human H1N1 virus was found to increase viral replication and
worsen histopathologic findings in the lower respiratory tract in
ferrets (16). Likewise, a reassortant virus containing the polymer-
ase genes (encoding PB2, PB1, and PA) of the highly pathogenic
H5N1 isolate A/Vietnam/1203/2004 (referred to as VN1203), iso-
lated from a fatal human infection, and the nonpolymerase genes
of A/chicken/Vietnam/C58/04 (H5N1) (referred to as CH58), an
HPAI isolate that is nonlethal in mice and ferrets, retained signif-
icant lethality in these animals. In contrast, a virus containing the
polymerase genes of CH58 and the nonpolymerase genes of
VN1203 was entirely nonlethal even though both viruses express
an HA with a polybasic cleavage site insertion (31), the principal
determinant of high pathogenicity in poultry infections (32).
The 2009 pandemic H1N1 virus possesses a PB2 protein of
relatively recent avian derivation, and this protein retains the
avian consensus residues PB2-627E and -701D. There has been
concern that the 2009 pandemic H1N1 virus could acquire
human-adaptive changes at these residues (33), and two viral iso-
lates with the PB2-E627K mutation have been reported (34). It is
therefore critical to assess the likelihood that pandemic H1N1
viruses with such mutations would have increased virulence.
RESULTS
To evaluate replicative properties and virulence factors specifically
attributable to the RNP complex of the 2009 pandemic H1N1
virus, we generated a reassortant virus containing the four RNP
genes (encoding PB1, PB2, PA, andNP) of a representative isolate,
A/California/04/2009 (H1N1) (referred to as CA09), on the back-
ground of the remaining four gene segments—encoding the hem-
agglutinin (HA), neuraminidase (NA),matrix (M), and nonstruc-
tural (NS) proteins—from a recent seasonal human influenza
virus, A/New York/312/2001 (H1N1) (referred to as NY312) (15);
we term the reassortant virus CA09RNP. Isogenic chimeric vi-
ruseswere chosen to control for differences inHA that could affect
cellular tropism and pathogenicity in vivo. As positive controls of
RNP-attributable virulence, viruses containing the RNPs of the
1918 pandemic (1918RNP) and VN1203 (VN1203RNP) viruses
were also constructed on the NY312 background. To assess the
impact of the PB2-E627K change on an RNP of nonmammalian-
adapted, avian origin, we generated a virus with the appropriate
segments from the low-pathogenicity avian virus A/green-winged
teal/Ohio/175/1986 (H2N1) on the NY312 background, termed
S09RNP. As a further control, the parental NY312 virus (rNY312)
was also rescued. Characteristics of the viruses evaluated in this
study are shown in Table 1.
To test the hypothesis that introduction of PB2 mutations at
residue 627 or 701 into the RNP of the 2009 pandemicH1N1 virus
would enhance virulence, we evaluated replication kinetics and
pathogenicity. First, we observed the growth of rescued viruses in
cell culture. All rescued viruses propagated well in MDCK cells
(data not shown). To characterize the chimeric viruses in cells of
human origin, replication kinetics in the A549 lung cell line were
assessed (Fig. 1). As expected, the 1918RNP virus grew to a signif-
icantly higher (1 log) mean peak titer than the control rNY312
virus (P 0.0083). The CA09RNP virus grew to high titers similar
to those of the 1918RNP virus (P  0.0088 for comparison to
rNY312), as did the VN1203RNP virus (P 0.019 for comparison
to rNY312), but the low-pathogenicity avian RNP genes (S09RNP
virus) did not show significantly enhanced growth compared to
theNY312 parent (P 0.050) (Fig. 1). To determine the impact of
host-adaptive mutations on replication, further selected isogenic
pairs of viruses in which PB2 residue 627 or 701 was mutated to
the mammalian or avian consensus residue as appropriate were
then created. A 1918RNP virus in which PB2 residue 627 was
TABLE 1 Characteristics of viruses evaluated in this study
Name Genotype
Nadir wt
(% of baseline)
Lung titer (PFU/g)
Histopathology3 dpi 5 dpi
rNY312 NY312 0.62 2.6 103 2.7 103 Few inflammatory foci; very rare viral
antigen
rNY312-K627E NY312, PB2-K627E 0.57 4.1 103 3.5 103 Few inflammatory foci; very rare viral
antigen
1918RNP 1918RNP:NY312 15.9 7.7 105 6.5 105 Moderate-marked necrotizing bronchiolitis;
abundant bronchiolar viral antigen
1918RNP-K627E 1918RNP, PB2-K627E:NY312 0.54 4.4 104 2.6 105 Few inflammatory foci; minimal
bronchiolar viral antigen
VN1203RNP VN1203RNP:NY312 15.7 4.2 105 2.6 103 Moderate-marked necrotizing bronchiolitis;
abundant bronchiolar viral antigen
S09RNP S09RNP:NY312 4.93 5.2 104 1.4 102 Focal alveolitis; predominantly alveolar viral
antigen
S09RNP-E627K S09RNP, PB2-E627K:NY312 8.06 9.9 105 2.3 105 Mild bronchiolitis; moderate bronchiolar
viral antigen
CA09RNP CA09RNP:NY312 4.18 2.2 105 4.1 104 Mild, focal necrotizing bronchiolitis; low
levels of bronchiolar viral antigen
CA09RNP-E627K CA09RNP, PB2-E627K:NY312 0.83 1.1 103 4.3 102 Few inflammatory foci; very rare viral
antigen
CA09RNP-D701N CA09RNP, PB2-D701N:NY312 1.71 1.2 104 2.5 103 Few inflammatory foci; very rare viral
antigen
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“back-adapted” to the avian glutamic acid (1918RNP-K627E)
consistently grew to a 1- to 2-log-lower peak titer (P 0.042) than
the 1918RNP virus. Conversely, mutation of PB2 residue 627 in
the avian RNP S09RNP virus to the mammalian consensus resi-
due (S09RNP-E627K) had little effect on growth in A549 cells.
Next, the impact of the PB2-E627K (CA09RNP-E627K) and
D701N (CA09RNP-D701N) mutations on viruses containing the
2009 pandemic RNP was assessed. Surprisingly, rather than in-
creasing the growth of the CA09RNP virus, both of these mutant
viruses grew to a 1- to 2-log-lower peak titer than the parental
CA09RNP virus (P 0.0058 and 0.0075, respectively).
To evaluate pathogenicity in vivo, the panel of viruses was in-
tranasally inoculated into mice at a dose of 2  105 PFU. Daily
weights of infected mice were obtained (Fig. 2) as an indicator of
clinical disease, and lungs were collected to measure viral replica-
tion (Fig. 3) and observe histopathology (Fig. 4 and 5).
Unsurprisingly, rNY312 induced little clinical disease, as
judged by peak percent weight loss (0.62%). The unadapted avian
origin S09RNPvirus also caused a lowburden of disease, as judged
by weight loss (Fig. 2). Consistent with previous studies, viruses
containing the RNPs of 1918 and the HPAI H5N1 virus VN1203
(Fig. 2) caused the greatest clinical disease. The peak percent
weight loss of mice infected with 1918RNP (15.9%) was signifi-
cantly greater than those of mice infected with NY312 (P 
0.0001). Forty percent mortality was observed in mice inoculated
with VN1203RNP, while no mortality was observed in any other
experimental group. Introducing the avian-like PB2-K627E
change into the 1918RNP virus rendered the weight loss curve
similar to that observed for rNY312 (Fig. 2), while the introduc-
tion of the human-like PB2-E627K change into the S09RNP virus
increased weight loss somewhat, albeit not significantly (4.93%
versus 8.06%; P  0.10). CA09RNP-infected mice lost slightly
more weight than those infected with rNY312, but the difference
was not statistically significant (4.18% versus 0.62%; P  0.23).
Compared to wild-type CA09RNP, CA09RNP-E627K and
CA09RNP-D701N induced similarly mild weight losses.
The replicative capacity of these viruses in mouse lung tissue
was assessed by titration of lung homogenate from 3, 5, and 7 days
postinoculation (dpi). The rescued wild-type human seasonal
H1N1 virus, rNY312, grew to a peak titer of 2.6 103 PFU/g at 3
dpi. Significantly higher peak titers were achieved by both
VN1203RNP (4.2 105 PFU/g; P 0.0055) and 1918RNP (7.73
 105 PFU/g; P 0.023) (Fig. 3). As expected, mutations at PB2-
627 significantly affected viral replication in mouse lung tissue.
FIG 1 Viral replication kinetics in A549 cells at 37°C. Cells were infected at a 0.01multiplicity of infection. Supernatants from infected A549 cells were collected
at 12-h intervals, and viral titer was determined by a plaque assay. Cultures and measurements were performed in triplicate. Titers are expressed as numbers of
PFU per milliliter. Error bars represent standard errors of the means (SEM). See the key for the different viruses evaluated.
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Compared to wild-type S09RNP, the S09RNP-E627K virus repli-
cated to approximately 1.5-log-greater titers on day 3 (9.9  105
versus 5.2 104 PFU/g; P 0.025) and 3-log-greater titers on day
5 (2.27  105 versus 1.4  102 PFU/g; P  0.023) (Fig. 3). Con-
versely, 1918RNP-K627E virus replication inmouse lung on day 3
was attenuated bymore than 1 log compared to thewild-type 1918
RNP-containing virus (7.73 105 versus 4.41 104 PFU/g; P
0.019) (Fig. 3) but by day 5 was within 0.5 log of the level for
wild-type 1918 RNP (6.53  105 versus 2.6  105 PFU/g; P 
0.21). No virus was detected in any lung on day 7.
The CA09RNP virus also grew to significantly higher peak ti-
ters than rNY312 (2.21 105 versus 2.6 103 PFU/g; P 0.043),
confirming the replication competence of this chimeric virus in
vivo. Again, to our surprise, introduction of the mammalian-
adaptive PB2-E627K or -D701N mutation into the pandemic
RNP significantly attenuated viral replication in mouse lung.
CA09RNP-E627K and CA09RNP-D701N reached approximately
2- and 1-log-lower peak titers than the wild-type CA09RNP virus,
respectively (1.1  103 and 1.24  104 PFU/g versus 2.21 
105 PFU/g; P 0.042 and 0.049) (Fig. 3).
The histopathology and viral antigen distribution of infected
mouse lung tissue were also characterized by analyzing formalin-
fixed, stained sections. Consistent with rNY312’s mild clinical ill-
ness and relatively low lung replication levels, rNY312-inoculated
lungs were predominantly within normal limits (Fig. 4), demon-
strating only mild focal changes and very rare viral antigen stain-
FIG 2 Clinical course of infection in mice as measured by weight loss. Mean percentage body weight loss from mean baseline weight of mice in each group
inoculatedwith rescuedA/NewYork/312/2001 (H1N1) (referred to as rNY312) or chimeric viruses containing the four RNP gene segments of different influenza
viruses on the NY312 background (see key) from 0 to 14 days postinoculation (dpi). Groups of five 8- to 10-week-old female BALB/c mice were inoculated
intranasally with 2 105 PFU of virus. Error bars represent SEM.
FIG 3 Viral titer inmouse lung tissues. Mean viral titer inmouse lung on days 3
and 5 postinfection was determined by a plaque assay. Data were collected from
threemice in each group.Titers are expressed asnumbers of PFUper gramof lung
tissue. Error bars represent SEM. See the key for the different viruses evaluated.
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FIG 4 Pathology and immunohistochemistry of influenza virus-infected mouse lung tissue. Photomicrographs of hematoxylin-and-eosin-stained tissue
sections and immunohistochemically stained sections for detection of influenza viral antigen frommice infected with different influenza virus constructs at day
5 postinfection. Viral antigen is stained reddish brown on a hematoxylin-stained background. Arrows and arrowheads show examples of positive cells. (A, B)
Sections from an animal infected with the rNY312 virus showing no pathological changes in the lung and no viral antigen (original magnifications,100). (C,
D) Sections from an animal infected with the 1918RNP virus showing marked necrotizing bronchiolitis with a marked transmural inflammatory cell infiltrate.
Prominent viral antigen staining was observed in bronchiolar epithelial cells (arrow) and in necrotic intraluminal debris (arrowhead) (original magnifications,
200). (E, F) Sections from an animal infected with the CA09RNP virus showing focal bronchiolitis with a minimal inflammatory cell infiltrate. Viral antigen
staining was observed in bronchiolar epithelial cells (arrow) and in necrotic intraluminal debris (arrowhead) (original magnifications,100). (G, H) Sections
from an animal infected with the CA09RNP-E627K virus showing no pathological changes in the lung and no viral antigen (original magnifications,100).
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FIG 5 Pathology and immunohistochemistry of influenza virus-infected mouse lung tissue. Photomicrographs of hematoxylin-and-eosin-stained tissue
sections and immunohistochemically stained sections for detection of influenza viral antigen frommice infected with different influenza virus constructs at day
5 postinfection (except for the VN1203RNP virus, which is shown at day 3 postinfection). Viral antigen is stained reddish brown on a hematoxylin-stained
background. Arrows show examples of positive cells. (A, B) Sections from an animal infectedwith the S09RNP virus showing a focus ofmoderate alveolitis. Focal
viral antigen is seen in bronchiolar epithelial cells (arrow) and in alveolar macrophages (original magnifications,100). (C, D) Sections from an animal infected
with the S09RNP-E627K virus showing necrotizing bronchiolitis with a transmural inflammatory cell infiltrate. Viral antigen staining was observed in bron-
chiolar epithelial cells (arrow) and in alveolar macrophages (original magnifications,100). (E, F) Sections from an animal infected with the VN1203RNP virus
at day 3 postinfection showing marked necrotizing bronchiolitis with a marked transmural inflammatory cell infiltrate. Prominent viral antigen staining was
observed in bronchiolar epithelial cells (arrow) (original magnifications,100). Similar histopathological changes were observed at day 5, but only limited viral
antigen staining was observed (data not shown). (G,H) Sections from an animal infected with the 1918RNP-K627E virus showing no pathological changes in the
lung but some viral antigen staining in bronchiolar epithelial cells (arrow) in the absence of inflammation (original magnifications,100). (I, J) Sections from
an animal infected with the CA09RNP-D701N virus showing no pathological changes in the lung and no viral antigen (original magnification,100).
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ing. In contrast, and consistent with previous studies, 1918RNP-
and VN1203RNP-inoculated mouse lungs exhibited a pattern of
moderate-to-marked necrotizing bronchiolitis with prominent
peribronchiolar infiltrates and abundant bronchiolar viral antigen
staining (Fig. 4 and 5). As with in vivo viral replication, mutations
at PB2-627 resulted in significantly different histopathological
patterns. The 1918RNP-K627E virus, for example, induced al-
most no inflammatory changes, resembling the findings seen with
rNY312. Introduction of the PB2-E627K change into the low-
pathogenicity avian S09RNP virus also altered histopathology.
Whereas the wild-type S09RNP virus gave rise to a focal alveolitis
with viral antigen in alveolar epithelial cells, the S09RNP-E627K
virus instead induced a mild bronchiolitis with increased levels of
bronchiolar antigen staining and no alveolitis (Fig. 5).
The CA09RNP virus induced a focal bronchiolitis with a min-
imal inflammatory infiltrate in infected animals and a predomi-
nantly bronchiolar pattern of moderate viral antigen staining
(Fig. 4). The introduction of either PB2-E627K or -D701N dimin-
ished these findings, resulting in a histopathological picture that
was predominantly within normal limits, displaying only rare,
focal inflammation (Fig. 4 and 5). Viral antigen staining was rare
in lungs infected with either mutant virus.
DISCUSSION
The 2009 H1N1 swine-origin pandemic virus has thus far been
relatively mild in its clinical severity, but the fact that it continues
to lack certain changes associated with high virulence and host
adaptation in other influenza viruses has remained a source for
concern. We show that in both A549 cell culture and a mouse
model of influenza infection, two of these changes, PB2-E627K
and -D701N, do not potentiate the replication or virulence of a
virus containing the 2009 pandemic RNP. Rather, both of these
changes significantly impair the replication of the virus and di-
minish the histopathological consequences of infection. Our find-
ings suggest that if the 2009 pandemic virus were to acquire these
changes, greater virulence would be an unlikely consequence.
In this study, we have evaluated a series of different RNP gene
sets on the same non-RNP background, namely, that of a seasonal
human H1N1 virus. Importantly, the wild-type 2009 H1N1 pan-
demic RNP-containing virus grew to high titers in both cell cul-
ture and mouse lung, confirming that the chimeric set of gene
segments was compatible and replication competent. Consistent
with previous reports, the RNP genes from both the 1918 pan-
demic virus and a representative HPAI H5N1 lineage virus,
VN1203, significantly enhanced pathogenicity. Particularly inter-
esting is the fact that qualitatively different histopathological pic-
tures can be induced with identical HA and NA genes: 1918 and
VN1203 RNPs induced a necrotizing bronchiolitis, whereas the
parental rNY312 virus did not. In the case of the 1918 RNP, this
property proved to be dependent on the presence of PB2-627K, as
the 627E mutant virus produced very little clinical or histopatho-
logical disease, despite replicating to relatively high titers. In yet
another context, that of the avian S09 RNP, the PB2-E627K mu-
tation changed the dominant histopathology from an alveolitis to
a bronchiolitis, while the identical mutation was detrimental to
pathogenicity in the setting of the CA09 RNP. Thus, the impact of
the PB2-627 genotype is at least partly a product of the surround-
ing ribonucleoprotein genetic context.
A recently published study likewise demonstrated neither any
potentiation of viral replication or pathogenicity in 2009 H1N1
pandemic viruses due to PB2-E627K or -D701N inmice or ferrets
nor any potentiation of transmission in ferrets (35). Thus, while it
is unexpected that the PB2-E627K and -D701Nmutations, shown
to be beneficial to viral replication inmammalianmodels in other
contexts, attenuate viruses containing the 2009 H1N1 pandemic
RNP, it is becoming clear that viral RNP adaptation to humans
can be achieved through routes other than PB2-627K or -701N.
Indeed,Mehle andDoudna have recently proposed such a residue
627-independent strategy, the so-called “SR” polymorphism, in-
volving residues 590 and 591 (36). It is hypothesized that both
strategies may operate by preserving a large positively charged
surface domain, implying that this region is involved in interac-
tions with undetermined host-specific factors. Interestingly, when
Mehle andDoudna introduced the SRmutations alongside E627K
in the avian S09 RNP background, no detriment to viral replica-
tion was observed in tissue culture, in contrast to the impaired
replication thatwe observed for viruses containing the 2009H1N1
RNP. Structural modeling of the 2009 H1N1 PB2 protein may
shed light on the underlying mechanism for these findings. Like-
wise, further biochemical characterization of wild-type and mu-
tant IAVpolymerases in different host cell environmentsmay help
elucidate the viral processes that are optimized via host adaptive
changes.
Thus, the present findings are consistent with our evolving
understanding of host switch events in influenza, i.e., that the
formation of pandemic influenza viruses, or the emergence of
novel swine influenza virus lineages, are independent polygenic
processes (37). Evolutionary analyses have demonstrated little ev-
idence of either parallel or convergent mutations in such events,
suggesting a strong role for historical contingency in the origina-
tion of any particular host-switch genotype (30). Instead, muta-
tions identified as important in one host switch event may or may
not be observed in other such events, depending on the viral and
host genetic context of each event (30).
While the PB2-E627K mutation clearly carries great signifi-
cance, it was insufficient to increase replication of an avian RNP-
containing virus in human cell culture. Similarly, the K627E back-
mutation in the context of rNY312 did not decrease its replication
competence in vitro or in vivo. Moreover, the status of PB2-627
does not by itself determine the viral replication or histopatholog-
ical phenotype; rNY312 and 1918RNP both possess a lysine at
PB2-627 yet exist at opposite ends of those spectra in the present
study. Perhapsmost intriguingly, in the case of the virus pair com-
prising 1918RNP and 1918RNP-K627E, a disconnect is observed
between the clinical disease and histopathology and viral replica-
tion: 1918RNP-K627E is only mildly attenuated in mouse lung
replication compared to 1918RNP, yet the 1918RNP-K627E virus
causes no clinical illness and virtually no histopathology. As this
represents the first known characterization of the 1918 RNP with
this mutation, further investigation of this phenotype is war-
ranted. Overall, we conclude that other virulence and host adap-
tive factors exist alongside PB2-627 as determinants of both host
adaptation and pathogenicity.
Future studies are needed to evaluate whether changes at resi-
due 627 or 701 in PB2 would be associated with enhanced trans-
missibility of the 2009 pandemic virus in humans, but the pan-
demic virus is clearly able to be transmitted in humans and in
animal model systems (35, 38, 39). This study also leaves open the
possibility that the pandemic virus could acquire other, yet-
undefined changes that could increase virulence and/or transmis-
PB2-E627K and the 2009 H1N1 Pandemic Virus Polymerase
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sibility. Further investigations into the functional significance of
these and other host- and virulence-associated genotypes will
therefore be key to understanding and combating this important
pathogen.
MATERIALS AND METHODS
Generation of synthetic viruses.Viral genome segments were cloned and
viruses were rescued as previously described (15, 40). Primers were syn-
thesized (Eurofins-Operon, Huntsville, AL) and mutations introduced
into reverse genetics plasmids using aQuikChange site-directedmutagen-
esis kit according to the manufacturer’s instructions (Stratagene, La Jolla,
CA). The presence of the introduced mutations and the identity of res-
cued viruses were verified by sequencing of segments 1 and 4.
Propagation and titration of viruses. Viruses were passaged 1 to 3
times on MDCK (ATCC) cells in the presence of 1 g/ml N-tosyl-l-
phenylalanyl chloromethyl ketone (TPCK)-treated trypsin in Dulbecco’s
modified Eagle’s medium (DMEM). Infectious titers of virus stocks were
determined by a plaque assay performed in triplicate according to stan-
dard protocols.
A549 viral replication kinetics. Triplicate sets of 80% confluent
monolayers of A549 (ATCC) cells were inoculated at a multiplicity of
infection of 0.01, washed with sterile phosphate-buffered saline (PBS),
and overlaid with Opti-MEM (Invitrogen, Carlsbad, CA) supplemented
with bovine serum albumin (0.2%) and 1 g/ml TPCK-treated trypsin.
Cells were incubated at 37°C and supernatants sampled at 12-h intervals
through 72 h and every 24 h thereafter until 120 h. Infectious titers of
supernatants were determined using a plaque assay. Paired t tests were
performed using GraphPad QuickCalcs, and graphical analysis was ac-
complished using GraphPad Prism (GraphPad Software Inc., La Jolla,
CA).
BALB/c mouse infection. All animal experiments were performed in
an enhanced animal BSL3 laboratory at the National Institutes of Health
under the auspices of anNIHAnimal Care andUse Committee-approved
animal study protocol. Groups of 5 8- to 10-week-old female BALB/cmice
(JAX Mice and Services, Bar Harbor, ME) were inoculated intranasally
with 2  105 PFU of virus in 50 l DMEM under light isoflurane anes-
thesia. Each mouse was weighed daily; mice losing 25% or more of their
body weight compared with the level observed on the day of inoculation
were humanely euthanized. Fivemice per viruswere euthanized ondays 3,
5, and 7 postinoculation and lungs collected; three sets of lungs were
frozen for virus titration, and two sets were inflated and fixed in 10%
neutral buffered formalin for histopathological analysis. Lung viral titers
were determined by weighing and homogenizing whole lungs in a 10%
(wt/vol) suspension of L15medium and titrating the homogenate using a
plaque assay.
Histopathological analysis. Formalin-fixed mouse lungs were dehy-
drated and embedded in paraffin and 5-m sections cut and applied to
positively charged slides (American HistoLabs, Gaithersburg, MD). The
sections were stained with hematoxylin and eosin and evaluated by a
single blinded pathologist. For immunohistochemical staining, antigen
retrieval was accomplished in a 10 mM sodium citrate-0.05% Tween 20
buffer using a 2100 Retriever model pressure cooker according to the
manufacturer’s instructions (Pickcell Laboratories, Amsterdam, Nether-
lands). The primary antibody was a goat polyclonal anti-influenza A virus
IgG (Abcam, Inc., Cambridge, MA), while the secondary antibody was a
biotinylated anti-goat IgG (Vectastain elite ABC kit; Vector Laboratories,
Burlingame, CA). A 3,3= diaminobenzidine (DAB) chromogen was used,
and the slides were counterstained using hematoxylin.
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